A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy

NCT05276297 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

174

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis B, Chronic

Interventions

DRUG: GSK3228836
BIOLOGICAL: GSK3528869A
DRUG: Control

Sponsor

GlaxoSmithKline